×
Ted Smolenski

Ted Smolenski

Vice President - Business Development

Ted Smolenski joined Slayback in June 2019, bringing approximately 20 years of pharmaceutical experience to the company.  He leads
Slayback’s business development efforts by identifying partnership opportunities and driving business deals to successful close.

Most recently, Mr. Smolenski was Head of Business Development at Rhodes Pharmaceuticals, where he played a lead role in business
development and alliance management.  Prior to Rhodes, Mr. Smolenski was Putney’s Vice President of Business Development and Portfolio
where he led Putney’s portfolio process and closed business deals to drive Putney’s growth.  Earlier in his career, Mr. Smolenski was
Senior Director of Portfolio Management and Strategy at Impax Laboratories where his team had responsibility for portfolio strategy,
alliance management, API sourcing, and PIV settlement negotiation.

Mr. Smolenski holds a Bachelor’s Degree in Civil Engineering and a Master’s of Business Administration from the University of Delaware.

Copyright ©2021 all rights reserved

Hydroxyprogesterone

On April 6, 2023, the U.S. Food and Drug Administration (FDA) issued a final decision ordering the withdrawal of the approval of Makena® (hydroxyprogesterone caproate injection, 250 milligrams (mg) per mL) and its generics. FDA recognizes that there is a supply of product that has already been distributed. Patients who have questions should talk to their healthcare provider. We recommend health care practitioners consider FDA’s conclusions.

If you have questions or concerns about receiving your therapy as prescribed, consult your healthcare provider.

https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena